Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

TERT (Telomerase Reverse Transcriptase)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

›

TERT amplification	Cutaneous Melanoma	TERT amplification	Cutaneous Melanoma	interferon α-2b Sensitive: B - Late Trials interferon α-2b Sensitive : B	interferon α-2b Sensitive: B - Late Trials interferon α-2b Sensitive : B
TERT mutation	Solid Tumor	TERT mutation	Solid Tumor	Immunotherapy Sensitive: C2 – Inclusion Criteria Immunotherapy Sensitive : C2	Immunotherapy Sensitive: C2 – Inclusion Criteria Immunotherapy Sensitive : C2
TERT 124C>T	Glioblastoma	TERT 124C>T	Glioblastoma	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
TERT mutation + MGMT promoter methylation	Glioblastoma	TERT mutation + MGMT promoter methylation	Glioblastoma	temozolomide Resistant: C3 – Early Trials temozolomide Resistant : C3	temozolomide Resistant: C3 – Early Trials temozolomide Resistant : C3
TERT promoter mutation	Urothelial Cancer	TERT promoter mutation	Urothelial Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
TERT amplification	Diffuse Large B Cell Lymphoma	TERT amplification	Diffuse Large B Cell Lymphoma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
TERT promoter mutation + BRAF V600	Melanoma	TERT promoter mutation + BRAF V600	Melanoma	MEK inhibitor + BRAF inhibitor Sensitive: C3 – Early Trials MEK inhibitor + BRAF inhibitor Sensitive : C3	MEK inhibitor + BRAF inhibitor Sensitive: C3 – Early Trials MEK inhibitor + BRAF inhibitor Sensitive : C3
TERT mutation + AFP elevation	Hepatocellular Cancer	TERT mutation + AFP elevation	Hepatocellular Cancer	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3
TERT mutation	Hepatocellular Cancer	TERT mutation	Hepatocellular Cancer	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3	bevacizumab + atezolizumab Resistant: C3 – Early Trials bevacizumab + atezolizumab Resistant : C3
TERT mutation	Squamous Cell Carcinoma of Head and Neck	TERT mutation	Squamous Cell Carcinoma of Head and Neck	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
TMB-H + TERT promoter mutation	Urothelial Cancer	TMB-H + TERT promoter mutation	Urothelial Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PIK3CA mutation + TERT promoter mutation	Liposarcoma	PIK3CA mutation + TERT promoter mutation	Liposarcoma	trabectedin Resistant: C3 – Early Trials trabectedin Resistant : C3	trabectedin Resistant: C3 – Early Trials trabectedin Resistant : C3